Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durability of Immune Response to JYNNEOS Vaccine
NCT06366672Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Jun 2024
- Primary completion
- Sep 2026
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JYNNEOS in smallpox and mpox, sponsored by Washington University School of Medicine. Primary endpoints: Change in magnitude of the MVA-BN antigen-specific T cell response in the blood at day 395 and Change in magnitude of the MVA-BN antigen-specific antibody response in blood plasma at day 395. Started Jun 2024; status: active, not recruiting.
02
Drugs
JYNNEOS
03
Conditions
smallpoxmpox
Beyond the preview
Go deeper on NCT06366672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06366672.